Table 1.
Participant characteristics. Participants who contributed sufficient data to be included in analysis are compared with those who did not. Values are presented as n (%) except where otherwise indicated. P-values were obtained using the Chi [2] test.
| Characteristic | Participants included in analysis (n = 68) n (%) | Participants excluded due to not contributing sufficient data (n = 61) n (%) | P-value | |
| Age | mean ± SD | 58 ± 10 | 59 ± 13 | – |
| ≥65 years | 19 (27.9) | 24 (39.3) | 0.17 | |
| Sex | Female | 17 (25.0) | 18 (29.5) | 0.57 |
| Race | White | 46 (67.7) | 40 (65.6) | 0.78 |
| Black or African American | 14 (20.6) | 13 (21.3) | ||
| Hispanic/Latino | 1 (1.5) | 3 (4.9) | ||
| Asian | 4 (5.9) | 2 (3.3) | ||
| Other/Unknown | 3 (4.4) | 3 (4.9) | ||
| Education | Bachelor’s degree or above | 30 (44.1) | 21 (34.4) | 0.26 |
| Insurance | Private | 39 (57.4) | 21 (34.4) | 0.06 |
| Medicare | 21 (30.9) | 26 (42.6) | ||
| Medicaid | 6 (8.8) | 12 (19.7) | ||
| Self-pay | 2 (2.9) | 2 (3.3) | ||
| Type of MI | STEMI | 33 (48.5) | 23 (37.7) | 0.22 |
| NSTEMI type 1 | 35 (51.5) | 38 (62.3) | ||
| Conditions prior to admission | Cerebrovascular disease or stroke | 6 (8.8) | 7 (11.5) | 0.62 |
| Peripheral arterial disease | 2 (2.9) | 2 (3.3) | 0.91 | |
| Diabetes mellitus | 26 (38.2) | 30 (49.2) | 0.21 | |
| Hyperlipidemia | 35 (51.5) | 38 (62.3) | 0.22 | |
| Hypertension | 46 (67.7) | 45 (73.8) | 0.45 | |
| CABG | 4 (5.9) | 7 (11.5) | 0.26 | |
| PCI | 8 (11.8) | 15 (24.6) | 0.06 | |
| MI | 5 (7.4) | 19 (31.2) | <0.01 | |
| Ever smoker | 38 (55.9) | 34 (55.7) | 0.99 | |
| Cardiovascular disease (prior stroke/TIA, PAD, CABG, PCI, MI) | 16 (23.5) | 29 (47.5) | <0.01 | |
| Admission Characteristics | CABG | 13 (19.1) | 18 (29.5) | 0.17 |
| PCI | 53 (77.9) | 42 (68.9) | 0.24 | |
| Complete revascularization | 62 (91.2) | 43 (70.5) | <0.01 | |
| Heart failure | 8 (11.8) | 9 (14.8) | 0.62 | |
| Length of stay median (IQR) | 4.5 (3.0–10.0) | 5.0 (3.0–10.5) | – | |
| Antihypertensive Medications prescribed at discharge | ACEi/ARB | 37 (54.4) | 38 (62.3) | 0.37 |
| Beta blocker | 63 (92.7) | 57 (93.4) | 0.86 | |
| Diuretic | 23 (33.8) | 22 (36.1) | 0.79 | |
| Calcium-channel blocker | 7 (10.3) | 11 (18.0) | 0.21 | |
| Number of antihypertensive medications at discharge | 0–1 | 15 (22.1) | 9 (14.8) | 0.36 |
| 2 | 42 (61.8) | 37 (60.7) | ||
| 3–4 | 11 (16.2) | 15 (24.6) | ||
ACEi/ARB angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; CABG coronary artery bypass graft; MI myocardial infarction; NSTEMI non-ST-elevation myocardial infarction; PAD peripheral arterial disease; PCI percutaneous coronary intervention; STEMI ST-elevation myocardial infarction; TIA transient ischemic attack.